Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2020

Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2020

  • August 2020 •
  • 147 pages •
  • Report ID: 5974919 •
  • Format: PDF
Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2020

Summary
According to the recently published report ’Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2020’; Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) pipeline Target constitutes close to 40 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.

The report ’Nuclear Factor Erythroid 2 Related Factor 2 - Pipeline Review, H2 2020’ outlays comprehensive information on the Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 5 and 22 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Immunology, Metabolic Disorders, Oncology, Cardiovascular, Respiratory, Gastrointestinal, Genetic Disorders, Musculoskeletal Disorders, Ophthalmology, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Hematological Disorders and Toxicology which include indications Multiple Sclerosis, Psoriasis, Diabetic Nephropathy, Chronic Obstructive Pulmonary Disease (COPD), Systemic Sclerosis (Scleroderma), Chronic Kidney Disease (Chronic Renal Failure), Coronavirus Disease 2019 (COVID-19), Friedreich Ataxia, Huntington Disease, Mitochondrial Myopathy, Neurodegenerative Diseases, Non-Alcoholic Steatohepatitis (NASH), Osteoarthritis, Pulmonary Arterial Hypertension, Relapsing Remitting Multiple Sclerosis (RRMS), Retinal Degeneration, Type 2 Diabetes, Acne Vulgaris, Acute Respiratory Distress Syndrome, Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex), Age Related Macular Degeneration, Alport Syndrome, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Asbestosis, Aspiration Pneumonitis, Asthma, Atherosclerosis, Breast Cancer, Bullous Pemphigoid, Cardiomyopathy, Cerebral Vasospasm, Diabetic Complications, Diffuse Large B-Cell Lymphoma, Duchenne Muscular Dystrophy, Encephalomyelitis, Focal Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, IgA Nephropathy (Berger’s Disease), Ischemia Reperfusion Injury, Ischemic Stroke, Keloids, Kennedy’s Disease (Spinal and Bulbar Muscular Atrophy), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Lung Injury, Medulloblastoma, Metastatic Breast Cancer, Metastatic Melanoma, Neuroblastoma, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Osteoporosis, Ovarian Cancer, Parkinson’s Disease, Pervasive Developmental Disorder (PDD), Plaque Psoriasis (Psoriasis Vulgaris), Polycystic Kidney Disease, Post-Myocardial Infarction, Primary Progressive Multiple Sclerosis (PPMS), Prostate Cancer, Pulmonary Hypertension, Radiodermatitis, Refractory Medulloblastoma, Retinopathy, Sickle Cell Disease, Spinocerebellar Ataxia (SCA), Subacute Necrotizing Encephalomyelopathy (Leigh Disease), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- The report reviews Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) targeted therapeutics

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.